Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Strategy and Platform Evolution
REPL logo

RP1 BLA on Track with 33.6% Response Rate in Refractory Melanoma

REPL10-KFiling Date: 5/22/2025
Replimune Group, Inc.
Description

What this story covers

Replimune's 10-K details RPx oncolytic platform advancing RP1 toward FDA approval in anti-PD-1 failed melanoma (33.6% ORR), with $483.8M cash runway to Q4 2026. Pipeline focuses on skin/liver cancers; FY25 net loss $247.3M amid R&D ramp-up. Partnerships with BMS/Roche de-risk development; manufacturing in-house. Risks include trial delays and funding needs.

Story snapshot

CompanyReplimune Group, Inc.
TickerREPL
VariantStandard detailed
Duration12:21
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0001737953-25-000009

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in